Abiraterone acetate base comprehensive for treatment of oligometastatic hormone-sensitive prostate cancer: a case report and literature review

Jian CAO; Gongqian ZENG; Shusuan JIANG; Yu XIE; Weiqing HAN

Abiraterone acetate base comprehensive for treatment of oligometastatic hormone-sensitive prostate cancer: a case report and literature review / 中华泌尿外科杂志

Jian CAO; Gongqian ZENG; Shusuan JIANG; Yu XIE; Weiqing HAN.

Chinese Journal of Urology ; (12): 39-42, 2021.

Article in Chinese | WPRIM | ID: wpr-911172

ABSTRACT

ABSTRACT

Conclusion:

Patients with OlimHSPC who are not sensitive to traditional CAB treatment, ADT combined with abiraterone acetate neoadjuvant therapy and postoperative adjuvant therapy can be attempted.

Prostate cancer; Oligometastatic; Hormone-sensitive; Androgen deprivation therapy; Abiraterone acetate; Palliative transurethral resection of the prostate

Fulltext

XML

Search on Google

Full text: Available Index: WPRIM (Western Pacific) Type of study: Diagnostic study Language: Chinese Journal: Chinese Journal of Urology Year: 2021 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google

Full text: Available Index: WPRIM (Western Pacific) Type of study: Diagnostic study Language: Chinese Journal: Chinese Journal of Urology Year: 2021 Type: Article